Jiangsu Hengrui Medicine Business Model Canvas

Externalizing clinical and manufacturing capacity with CROs and CDMOs accelerates Hengrui timelines and adds flexibility, reducing fixed capital needs and enabling faster patient recruitment across regions. CROs now manage over 70% of clinical trial operations globally, ensuring multicenter coordination and data integrity at scale. CDMOs provide specialized biologics and sterile-injectable expertise, and robust quality agreements secure GMP compliance and supply continuity.

Hengrui leverages global pharma co-development and licensing to de-risk late-stage assets and access markets, with deal upfronts/milestones often >$100m and royalties 2–15%. University and hospital partnerships feed 200+ active trials and KOL support; R&D spend was RMB 8.6bn in 2023, with CROs handling >70% of trial operations by 2024. National distributors and GPOs secure cold-chain hospital coverage and drive tender access in 2024.

GMP manufacturing at Jiangsu Hengrui scales up small molecules, biologics and injectables to secure supply, supporting multi-site output and clinical-to-commercial batches; in 2024 the group maintained R&D investment of RMB 7.9 billion to feed pipelines. Process validation and continuous improvement cut batch failures and lower unit cost, while tech transfer from R&D to plants reduces variability across sites. Digital MES and QMS deployments improved oversight and traceability, aligning plant KPIs with regulatory standards.

Discovery to IND, Phase I–III trials and GMP scale-up drive Hengrui’s pipeline (oncology ~40% of clinical assets in 2024). R&D spend was RMB 7.9 billion in 2024; MSLs delivered 2,000+ engagements. Regulatory filings, HEOR and PV secure market access and reimbursement across China (basic medical insurance covers >95% in 2024).

Jiangsu Hengrui Medicine maintains multiple GMP-certified facilities for both small-molecule and biologic production. Sterile injectable lines and dedicated QC laboratories support batch reliability and regulatory compliance. Capacity is structured to serve large domestic demand and growing export markets, while digitalized manufacturing and MES/ERP traceability systems enhance yield and batch tracking.

Multidisciplinary R&D team supported RMB 8.1 billion R&D spend in 2023 and global regulatory experience. Patent portfolio >1,000 grants (2024) plus data exclusivity and trade secrets. Multiple GMP-certified sites with sterile injectable capacity and MES/ERP. Rich clinical datasets (VigiBase >30M ICSRs 2024) and strong hospital/KOL channels.

Strong manufacturing scale and integrated facilities drive cost efficiency at Jiangsu Hengrui, supporting value pricing that expanded patient reach; in 2024 the company reported revenue of RMB 44.5 billion, with GMP-compliant plants and ISO systems meeting global standards to ensure trust. Reliable supply chains and high production uptime minimize therapy interruptions, reinforcing affordable access to high-quality medicines.

Integrated value proposition: scalable manufacturing and RMB 44.5 billion 2024 revenue enable affordable pricing and reliable supply; 200+ clinical programs (2024) and 30+ registered oncology trials deliver pipeline continuity and earlier-line expansion; precision biomarker strategies, companion diagnostics and robust RWE drive payer/KOL uptake.

Patient support programs deliver access assistance, education, and digital adherence tools that improve outcomes; WHO estimates adherence to long-term therapies averages about 50% in developed settings. Financial support and co-pay assistance reduce treatment abandonment and lower out-of-pocket barriers. Dedicated pharmacovigilance channels feed real-world safety data into registries. Continuous patient feedback loops refine service design and targeting.

Dedicated key-account teams cover ~1,200 major hospitals (2024), aligning supply and formularies; MSLs and advisory boards drive clinical uptake while R&D >10% revenue (2023) informs evidence generation. Omnichannel digital nudges delivered +20% conversion in 2024 pilots; 24/7 adverse-event reporting meets NMPA/ICH SLAs.

Direct sales to key centers provide strategic accounts (hospital leaders and KOLs) with dedicated coverage for control and insight, aligned with Jiangsu Hengrui Medicine (Shanghai Stock Exchange: 600276). Specialized reps manage complex therapies and follow administration protocols. Ongoing training and in-servicing drive adoption. Captured CRM and patient-use data inform forecasting and inventory allocation.

Provincial/national tenders secure hospital formulary access; centralized pilots cut avg drug prices ~52% (2024). Distributors cover 31 provinces with cold-chain for biologics (2–8°C); sell-through KPIs drive incentives. Direct sales target key hospitals; CRM and patient-use data inform supply. Digital channels favored by ~65% HCPs (2024), supporting webinars and e-detailing.

National and provincial payers set reimbursement and tender access that determine volumes and pricing for Jiangsu Hengrui, with centralized procurement historically achieving price cuts up to 70%. HTA bodies assess value and budget impact, shaping NRDL inclusion and hospital adoption. Policy shifts in 2024 accelerated tender consolidation, influencing >95% of public hospital drug purchasing. Real-world outcomes and registry data now directly affect reimbursement renewals.

Tertiary hospitals (~3,000) drive early adoption (>60% complex oncology) and require 20–40 clinician-hours training. Prescribers (oncology, cardio, endocrinology) and KOLs dictate formulary placement; Hengrui reported RMB 54.2bn revenue in 2023 and international sales ~10% of 2024 revenue. Payers/tenders (>95% public procurement) force price cuts up to 70% and HTA-driven access.

Regulatory and market-access activities consume significant resources: submission preparation, fees and inspections drive personnel and external consultancy costs; Hengrui reported RMB 8.14 billion R&D spend in 2023, with regulatory/MA a material share. HEOR, HTA and pricing dossiers add ongoing expense and typically account for 10–20% of launch budgets. Post-marketing commitments and localization of dossiers for over 50 markets sustain recurring spend.

Discovery, preclinical and trials drive costs; R&D rose from about RMB 12.7bn in 2023 to a 2024 target near RMB 15bn, with CRO fees ~10–20% of trial budgets. Manufacturing (raw materials, biologics, sterile ops) and QA/QC create ongoing COGS pressure while capex and depreciation sustain fixed overheads. Commercial, regulatory/MA and HEOR/HTA (10–20% of launch budgets) add recurring spend.

Out-licensing by Jiangsu Hengrui yields upfronts, milestone payments and tiered royalties—upfronts often range from tens to hundreds of millions USD while royalties commonly fall between 5–20%. Co-development deals typically split R&D costs and upside (eg. ~50/50), sharing risk. IP monetization via sublicenses and territory rights extends revenue beyond direct sales. Milestone timing (often 3–7 years) materially affects cash flow timing.

Domestic drug sales were the core engine, ~78% of group revenue in 2024, led by oncology and chronic portfolios via hospital/pharmacy channels.

Exports and licensing contributed ~10–15% of sales; out‑licensing upfronts often tens–hundreds MUSD, royalties typically 5–20% with 3–7 year milestone timing.

Co‑promotions, bundled test‑plus‑drug models and companion diagnostics (global market $4.2B in 2024) provide ancillaries; 2023 revenue RMB 46.9bn.